Beam Therapeutics Q2 2026: Net Loss Widens, CEO Adopts 10b5-1 Plan, BEAM-302 Pivotal Cohort Dosed
BEAM sits 63% above its 52-week low of $15.6.
Summary
Beam Therapeutics posted a $122.7M Q2 net loss with $1.2B in cash. Clinical catalysts include BEAM-302 pivotal dosing and BEAM-304 IND clearance, but the CEO's adoption of a 10b5-1 trading plan introduces a potential overhang.
Key Events · Earnings and Guidance · BEAM
-
Q2 2026 Financial Results
Net loss of $122.7 million on revenue of $0.5 million. Cash, equivalents, and marketable securities totaled $1.2 billion as of June 30, 2026, expected to fund operations for at least 12 months.
-
CEO Adopts 10b5-1 Trading Plan
CEO John Evans adopted a Rule 10b5-1 plan on June 16, 2026, for the potential sale of up to 200,000 shares through June 30, 2027.
-
BEAM-302 Pivotal Cohort Initiated
The first patient was dosed in the pivotal expansion cohort of the BEAM-302 Phase 1/2 trial in July 2026, supporting a potential accelerated approval pathway in AATD.
-
BEAM-304 IND Cleared
The FDA cleared the IND for BEAM-304 in June 2026, and clinical startup activities have begun for a Phase 1/2 trial in phenylketonuria.
Analysis · BEAM · Life Sciences
A net loss of $122.7 million on minimal revenue underscores the pre-commercial stage, yet a $1.2 billion cash position provides ample runway. Clinically, the quarter delivered two milestones: dosing began in the BEAM-302 pivotal cohort, and the FDA cleared the IND for BEAM-304, allowing Phase 1/2 startup activities to commence. Tempering the outlook, CEO John Evans adopted a Rule 10b5-1 trading plan covering up to 200,000 shares. Meanwhile, the Apellis collaboration concluded, and Biogen closed its acquisition of Apellis. The balance sheet carries $100.3 million in debt from a new credit facility. Updated risk factors flag ongoing CRISPR patent interference proceedings that could challenge Beam's intellectual property.
At the time of this filing, BEAM was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $15.60 to $38.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.